Lilly has been chasing—and gaining on—its chief metabolic medicine rival Novo Nordisk and its counterpart GLP-1s Ozempic and ...

Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored ...

The Trump Administration is pursuing decidedly anti-growth policies. The results will be a weaker economy that violates his ...

Aside from the MFN order, President Trump is also in the process of negotiating tariffs with countries all over the world. It ...

German drugmaker Merck KGaA on Thursday joined peers in saying it was considering distribution models that serve U.S.

From sweeping hikes to public barbs over Russian oil, the US  president’s latest policy barrage is reshaping India-US relations and redrawing the contours of global trade and strategic power ...

The Arizona congressional delegation should stand up for our bioscience sector and oppose any policy like Most Favored Nation ...

It’s a bad time to try to predict future pharmaceutical prices.

The U.S. government has been discussing with drugmakers how to raise overseas drug prices as President Donald Trump seeks to ...

The threat comes as Trump's administration pressures pharmaceutical companies to lower drug prices for Americans.

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...

Trump’s MFN price controls on drugs will harm U.S. companies and patients.